Superworth

Gilead Sciences revenue GILD

Sales by quarter and over the last twelve months, from 1995.

Last 12 months, to Sep 30, 2026
$31B
Latest quarter, Q3 FY26
$8.3B
+7% on a year earlier
Fiscal year 2025
$29.4B
+2% on the year before

Gilead Sciences' revenue was $31B over the twelve months to Sep 30, 2026, up 7% on a year earlier.

In its latest quarter, Q3 FY26, it was $8.3B, up 7% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 4% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$29.4B+2%
FY2024$28.8B+6%
FY2023$27.1B−1%
FY2022$27.3B−0%
FY2021$27.3B+11%
FY2020$24.7B+10%
FY2019$22.4B+1%
FY2018$22.1B−15%
FY2017$26.1B−14%
FY2016$30.4B−7%
FY2015$32.6B+31%
FY2014$24.9B+122%
FY2013$11.2B+15%
FY2012$9.7B+16%
FY2011$8.4B+5%

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$8.3B+7%$31B
Q2 FY26$7.8B+10%$30.5B
Q1 FY26$7B+4%$29.7B
Q4 FY25$7.9B+5%$29.4B
Q3 FY25$7.8B+3%$29.1B
Q2 FY25$7.1B+2%$28.9B
Q1 FY25$6.7B−0%$28.7B
Q4 FY24$7.6B+6%$28.8B
Q3 FY24$7.5B+7%$28.3B
Q2 FY24$7B+5%$27.8B
Q1 FY24$6.7B+5%$27.4B
Q4 FY23$7.1B−4%$27.1B

Against its peers

Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
GILDGilead Sciences$31B+7% a year
AMGNAmgen$38.1B+9% a year
PFEPfizer$63.7B−0% a year
BMYBristol-Myers Squibb$50B+4% a year
MRKMerck$67.4B+5% a year
ABBVAbbVie$66B+11% a year
JNJJohnson & Johnson$99.3B+8% a year
BIIBBiogen$10B+0% a year
LLYEli Lilly and$86.5B+46% a year
Peer median$64.9B

Where Gilead Sciences ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Gilead Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.